Recursion Pharmaceuticals

Recursion Pharmaceuticals Change in Working Capital

The Change in Working Capital of Recursion Pharmaceuticals (RXRX) as of Nov 11, 2026 is 13.69 M USD. In the previous year, Change in Working Capital was -38.00 M USD — a change of -136.02% (higher).

Change in Working Capital

13.69 MUSD

YoY

-136.02%

Last updated:

Change in Working Capital of Recursion Pharmaceuticals is 2025 13.69 M USD. Change in Working Capital of Recursion Pharmaceuticals was 2024 -38.00 M USD. It decreases by -136.02% higher compared to the previous year.

The Recursion Pharmaceuticals Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2019
408,000.00 USD
Jan 1, 2020
30.83 M USD
Jan 1, 2021
-306,000.00 USD
Jan 1, 2022
104.92 M USD
Jan 1, 2023
-44.26 M USD
Jan 1, 2024
-38.00 M USD
Jan 1, 2025
13.69 M USD
The Recursion Pharmaceuticals Change in Working Capital history
YEARChange in Working CapitalYoY
13.69 MUSD-136.02%
-38.00 MUSD-14.14%
-44.26 MUSD-142.18%
104.92 MUSD-34,387.91%
-306,000.00USD-100.99%
30.83 MUSD+7,457.35%
408,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals, Inc. makes money by developing novel therapeutics through its Recursion Operating System (OS), which integrates automation, artificial intelligence, machine learning, and in vivo validation. The company focuses on discovering medicines using advanced technologies in biology, chemistry, automation, and computer science. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, with REC-994 being an orally bioavailable, superoxide scavenger small molecule for treating cerebral cavernous malformations. The company generates revenue from its platform and clinical development efforts, targeting biopharmaceutical partnerships and potential future drug sales. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, leveraging its Recursion Data Universe to map biological and chemical relationships. The Recursion Operating System (OS) enables the company to rapidly translate silico hypotheses into validated insights and novel chemistry through iterative loops of wet lab biology and chemistry data. The company's platform integrates physical and digital components to create virtuous cycles, driving the discovery of novel therapeutics. Revenue is derived from its technology platform and clinical programs, with potential partnerships in the biopharmaceutical sector. The company's primary products are its Recursion Operating System (OS) and clinical programs such as REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is a small molecule designed for cerebral cavernous malformations, while the other programs are part of its broader therapeutic pipeline. The company targets biopharmaceutical companies and research institutions as potential partners for its technology and drug development services. Recursion Pharmaceuticals, Inc. monetizes its platform through licensing agreements and collaborative research deals, focusing on the discovery of novel medicines using AI-driven approaches. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recursion Pharmaceuticals stock

Change in Working Capital of Recursion Pharmaceuticals is 13.69 M USD in 2025.

Change in Working Capital of Recursion Pharmaceuticals changed from -38.00 M USD to 13.69 M USD, representing a -136.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Recursion Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Recursion Pharmaceuticals

All Key Metrics — Recursion Pharmaceuticals